Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 3/20 | 0.37 |
| ▸ | BCR | P11274 | 3/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 9/20 | 0.37 |
| ▸ | GALR2 | O43603 | 1/20 | 0.36 |
| ▸ | GALR1 | P47211 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14800005 | 0.91 | CYP4F2 (0.37) | CYP4F2CYP4A11ABL1BCRALOX5AP | |
| SCHEMBL24013115 | 0.79 | CYP4F2 (0.47) | CYP4F2CYP4A11 | |
| SCHEMBL24012651 | 0.72 | LSS (0.38) | CYP4F2CYP4A11 | |
| SCHEMBL26131596 | 0.71 | CYP4F2 (0.38) | CYP4F2CYP4A11 | |
| SCHEMBL30616252 | 0.71 | CYP4F2 (0.38) | CYP4F2CYP4A11 | |
| SCHEMBL14804123 | 0.71 | SMO (0.40) | ABL1BCRSYK | |
| SCHEMBL21218011 | 0.70 | GRM4 (0.39) | CYP4F2CYP4A11SYK | |
| SCHEMBL21217786 | 0.69 | GRM4 (0.40) | CYP4F2CYP4A11SYK | |
| SCHEMBL14800725 | 0.69 | MAPT (0.45) | ABL1BCRSYK | |
| SCHEMBL24012457 | 0.68 | CYP4F2 (0.46) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841301-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130079338-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079338-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | CYP4F2 1592/4885CYP4A11 2947/4885ABL1 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.